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Edited by Stuart FergusonAbstract In many vertebrate tissues, cytosolic 5 0-nucleotidase
II (cN-II) either hydrolyses or phosphorylates a number of pur-
ine (monophosphorylated) nucleosides through a scheme common
to the Haloacid Dehalogenase superfamily members. It possesses
a pivotal role in purine cellular metabolism and it acts on antitu-
moural and antiviral nucleoside analogues, thus being of potential
therapeutic importance. cN-II is Mg2+-dependant, regulated and
stabilised by several factors such as allosteric eﬀectors ATP and
2,3-DPG, although these are not directly involved in the reaction
stoichiometry. We review herein the experimental knowledge
currently available about this remarkable enzymatic activity.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The regulation of nucleotide pools is central to cellular ener-
getics, balance and replication. It relies on a variety of comple-
mentary enzymes of which 5 0-nucleotidases (5NT, EC 3.1.3.5)
are catabolic members that hydrolyse non-cyclic monophosph-
orylated nucleosides at the 5 0 position. The activity of 5NT has
been characterised in many organisms; among human 5NT se-
ven forms are identiﬁed to date. One of them is a ubiquitous
membrane-bound form (eN) and six are intracellular, Mg2+-
dependant enzymes with diﬀerent speciﬁcities and locations
[1,2]. Cytosolic 5 0-nucleotidase II (cN-II) is a (d)IMP,
(d)GMP preferring form that was also found active on adeno-
sine monophosphate (AMP) to some extent. It has been char-Abbreviations: 5NT, 5 0-nucleotidase; AMP, adenosine monophosphate;
Ap4A, adenosine(5
0)tetraphospho(50)adenosine; BPG, 2,3 bisphospho-
glycerate; cN-II, cytosolic 50-nucleotidase II; HAD, L-2-haloacid
dehalogenase; IMP, inosine monophosphate; mdN, mitochondrial
deoxyribonucleotidase; Pi, inorganic phosphate; PSP, phosphoserine
phosphatase
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doi:10.1016/j.febslet.2005.05.014acterised in mammals (rat, pig, calf, and human), birds
(chicken, goose) as well as a frog [3], the invertebrate Artemia
[4] and three ﬁsh species [5]. It is best documented in mammals
and birds where it has been described in various tissues [1,6],
including human (placenta [7], heart [8], erythrocytes [9] and
lymphoblasts). cN-II has a particularly elevated activity in
avian liver and in organs with a high turnover rate or DNA
replication including human colon carcinoma [10]. cN-II also
displays a phosphotransferase activity on several nucleosides
for which no kinase has been characterised yet, including ino-
sine and some antiviral and antitumoural nucleoside analogues
[10]. The structural features and complex regulatory mecha-
nism of this allosteric enzyme will be the focus of the present
review, together with both their implications in metabolism
regulation and therapeutic prospects.2. Sequence, structural features and mechanism
To date, cN-II cDNAs have been obtained from chicken liver
[11], human placenta [11] and calf thymus [12]. The identity be-
tween human and chicken sequences is 95% [11]; it reaches
99.6% between human and bovine sequences. The 561 bases
long human cDNA sequence obtained from human placenta
is predicted to correspond to a 65 kDa monomeric unit,
although SDS–polyacrylamide gel electrophoresis analyses
for cN-II from various sources are in the range 50–70 kDa
[13]. By studying cN-II from calf thymus as well as thrombin-
cleaved recombinant enzyme, Tozzi et al. recently identiﬁed
Arg547, an arginine residue at the C-terminal end, as a protease
target site. This accounts for the isolation of two separate cN-II
forms at 59 and 54 kDa [14], the regulation properties of which
are discussed hereunder. At standard stabilising conditions and
in the absence of eﬀectors, cN-II is a homotetramer.
Identiﬁcation of a phosphoester enzyme intermediate at
Asp52 [15] enabled both the identiﬁcation of the catalytic motif
and the recognition of cN-II as amember of theHaloacidDehal-
ogenase (HAD) superfamily [16], in which this motif is highly
conserved and phosphorylated during catalysis. The HAD
superfamily contains diverse hydrolases such as 2-HAD, phos-
phoserine phosphatase (PSP), the response regulator CheY
and P-type ATPases. They share three conserved motifs in their
otherwise dissimilar sequences (less than <10% identity); allation of European Biochemical Societies.
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members for which a structure is available, namely PSP (PDB
entry 1F5S) and mitochondrial deoxyribonucleotidase (mdN,
PDB entry 1MH9), evidences the role of these motifs in binding
and catalysis [17] (Fig. 1). Motif I is the DXDX(V/T)(L/V) cat-
alytic site in which the ﬁrst Asp is transiently phosphorylated
upon catalysis. Motif II is a (S/T) residue stabilising the phos-
phorylated intermediate. Motif III, K(G/S)(D/S)XXX(D/N),
has many charged residues of which Lys takes part in the inter-
mediate stabilisation and negatively charged residues interact
with themetallic cation.Froma sequence alignment of thesemo-
tifs in PSP, mdN and bovine cN-II, directedmutagenesis studies
on the latter conﬁrmed the similar role of its catalytic residues
[14].Hence,Asp54 (motif I) aswell asAsp351 andAsp356 (motif
III) coordinate Mg2+, while Met53 and Thr56 (motif I) enable
correct positioning of all Asp residues, whereas Thr249 (motif
II) and Lys292 (motif III) stabilise the phosphorylated interme-
diate. Moreover, based on structural studies of the mdN active
site, several additional residues are shown to take part in base
substrate recognition [17].
From a structural viewpoint, comparison of PSP and mdN
monomeric subunits evidences similar folds for both proteins
with two domains [17]: one large a/b pattern closely related to
the Rossman motif and a small four-helix bundle, the junction
of both domains homing the active site. Although no domainFig. 1. (a) Catalytic motifs in the cN-II sequence. Blue amino acids are cataly
uncharged residues with similarities in other HAD enzymes; red amino acids a
the number of omitted residues. (b) Catalytic amino acids in a schematic ac
Table 1
Physiological and kinetic data recorded for cN-II in various conditions
IMP A
Cellular concentrations (mM)
(a) Basal statea 0.02–0.3 0.
(b) Hypoxia, ischaemiab 0.2–0.6 >1
(c) After fructose loadc 2 
Kinetic propertiesd
S0.5 or A0.5 (mM)
(a) Standard conditionse 0.2–1.4 3–
(b) +Pi (2–5 mM) 0.5–7.2 49
(c) +ATP (1–5 mM) 0.02–0.4 2.
Vmax (lM/min mg) standard conditions
e 7–37 6–
Abbreviations: A0.5, eﬀector concentration for half maximal activation; S0.5,
a[38,53–56].
bIn rat/pigeon hearts [38,53,54,57].
cIn rat liver after 10 min fructose load [37,56]. When required, the conversion
wet tissue = 2.5 mL intracellular water.
d[1,7,13,25,58,59] on puriﬁed enzymes.
eStandard kinetic conditions include: pH 6.5–7.4; 300–600 mM NaCl/KCl arearrangement is clearly signiﬁcant in mdN, it has been pro-
posed that conformational changes occur in PSP that generate
a closed and an opened form of this enzyme [18]. Structural
changes in cN-II are equally likely [19] as apparent from its com-
plex allosteric regulation.3. Regulation
3.1. Nucleotidase kinetics and activation
All cN-II in native forms share similar kinetics proﬁles and
selectively hydrolyse 5 0-monophosphorylated nucleosides with
a marked aﬃnity for 6-hydroxypurine forms. cN-II requires
bivalent metallic cations to be active, preferably Mg2+, and
hydrolyses inosine monophosphate (IMP) with a usually
hyperbolic kinetic proﬁle in the presence of 10 mM Mg2+ or
a sigmoidal proﬁle at lower Mg2+ concentrations [20]. Half
activation concentration of Mg2+ is about 2 mM in the pres-
ence of 2–3 mM IMP. cN-II also hydrolyses other substrates,
such as AMP, through the same active site [21] although with
a markedly sigmoidal proﬁle in the latter case. Sigmoidicity of
the AMP kinetic proﬁle is independant of Mg2+ concentration.
Complementary to Mg2+ several phosphates donors display
an activator eﬀect on cN-II, such as adenylates (mainly
ATP), 2,3-bisphosphoglycerate (BPG) [9,22] or diadenosinetic residues conserved in other HAD enzymes; yellow amino acids are
re C-terminal residues involved in activity regulation. In parentheses is
tive site [14].
MP GMP ATP Pi
1–0.5 0.02–0.04 3–10 5–10
1–5 >20–30
0.4 1 <3
15 0.7–1.6 0.3–1.5 1.5
–64
6–15
26 6–30 n.a. n.a.
substrate concentration for half maximal activity; n.a., not applicable.
from lmol/g tissue to mM was estimated as follows: 1 g dry tissue = 5 g
nd 1–50 mM MgCl2.
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increasing Vmax and reducing Km values (Table 1) in a non-
additive manner under saturating conditions [9], which suggest
that they all act on the same site. Upon ATP addition, the AMP
kinetic proﬁle becomes hyperbolic and its Vmax is of the same
order of magnitude as for IMP. Nevertheless, IMP keeps a
markedly lower Km and does not depend upon ATP for hyper-
bolic kinetics. On the other hand, the amount of ATP necessary
for optimal activity is substrate-dependant; hydrolysis activa-
tion by ATP is cooperative at micromolar and hyperbolic at
millimolar IMP concentrations [7]. Under activating concen-
trations, ATP also protects the enzyme against thermal inacti-
vation or trypsin action [1]. It was equally found to protect the
active site from the carboxylate-speciﬁc Woodward Reagent K
[15], but this protection was removed by adding Mg2+ which
presumably increases the active site accessibility. Finally, as
well as stabilising the enzyme and enhancing Vmax, ATP fa-
vours an increase in cN-II autoassociation [13]. It should be
noted that ATP or other eﬀectors are not directly involved in
the reaction stoichiometry [10] but rather in allosteric regula-
tion, combined stabilisation and activation. Other multi-
charged compounds such as polyphosphates [23] and
decavanadate [24] were also found to activate cN-II in the same
mode as other activators.
Physiologically, Ap4A could be the main eﬀector as it acti-
vates the enzyme at concentrations two orders of magnitude
lower than ATP [4], but the physiological meaning of this acti-
vation is unclear [23]. As to BPG, though as potent as ATP in
heart, liver, brain, kidney and spleen [22], it is unlikely to play
any role in these tissues since it is only present at signiﬁcant
concentrations in erythrocytes.
In the absence of the precited eﬀectors, concentrations of
NaCl,KCl P 300 mMmimic their eﬀects by promoting the sta-
bilisation and aggregationof the enzyme [13], loweringKm for its
substrates (and increasingVmax in the case of IMP) especially in
the alkaline range. NaCl and KCl also render the AMP kinetic
proﬁle hyperbolic. In addition, several carboxylic acid Tris salts
(maleate, fumarate, and succinate) have similar, non additive ef-
fects [25] and one buﬀer preparation using 3-N-morpholino pro-
panesulfonic acid has been reported not to require any salt
addition for protein stabilisation [24].
Conversely, Pi has been reported to increase sigmoidicity
and S0.5 of the kinetic proﬁles [7], or to increase Km in the case
of hyperbolic proﬁles [26]. It presumably competes with the
substrate in the allosteric active site, or acts on the eﬀector site
[7]. ATP and Pi tend to counteract each other. Thus, varying
experimental conditions may be responsible for diﬀerent prop-
erties or contradictory behaviours of the enzyme.3.2. The role of the C-terminal end
In addition to being highly dependant on external condi-
tions, the regulation of cN-II also seems dependant on
C-terminal end particularities. A striking 13 residues-long
C-terminal acidic stretch (Fig. 1) was shown to enhance
both cN-II activation and autoassociation [13]. The acidic
tail is present in all cN-II forms and in the case of chicken
liver enzyme, nine more glutamate residues are even present
in that region [11]. In fact a cN-II mutated construct, with-
out this tail, was less responsive to eﬀector activation than
the full-length protein [13]. It was recently shown that a
thrombin-digested cN-II form, cleaved at the Arg526position and therefore lacking the C-terminal acidic stretch,
was activated by ADP and BPG in a synergistic manner that
diﬀers from that of the uncleaved enzyme [14]. On the other
hand, there are some diﬀerences between the mutated
construct and the cleaved cN-II of those separate studies:
the former showed a sizeable decrease in Vmax and increase
in Km for IMP compared to the full length protein, whereas
this diﬀerence was absent in the cleaved enzyme when no
eﬀector was used. Whether this contradiction is sequence-
related, or originates from experimental diﬀerences deserves
further interest and would, for instance, beneﬁt from struc-
tural insights [14].
An additional feature of the cleaved enzyme is its insensitiv-
ity to oxidative conditions. Indeed, it lacks a Cys547 residue
that can form a disulﬁde bridge with Cys175, under oxidative
conditions, which was shown to inhibit the uncleaved cN-II
[14]. Thus, the existence of a cleaved cN-II reported in calf thy-
mus could make the enzyme react diﬀerently under varying cel-
lular redox status.
The role of the C-terminal end and the eﬀect of Cys547-
Cys175 redox state might interestingly recall some speciﬁc
cases of redox intrasteric regulation. This concept was intro-
duced as a subclass of the allosteric model, to describe a pseu-
do-substrate domain of protein kinases capable of inhibiting
their own active sites [27]. It was extended to other regulated
enzymes. In some speciﬁc cases, intrasteric regulation appears
coupled to redox sensors such as disulfur bridges. In plants,
the speciﬁc case of NADP–malate dehydrogenase (NADP–
MDH) was best studied [28]. The crystal structure of inacti-
vated NADP–MDH [29] and the NMR study of its activation
by thioredoxin [30] evidenced the intrasteric inhibitory role of
the last two amino acids acting as a diacidic substrate-like moi-
ety, fully liberated from the active site upon reduction at the
appropriate potential.3.3. cN-II, a bifunctional enzyme
Besides its nucleotidase activity, cN-II also has a phospho-
transferase activity which proceeds from the free phosphoen-
zyme [20] through the binding of an appropriate phosphate
acceptor such as inosine or deoxyinosine. As those com-
pounds are better phosphate acceptors than water and as
hydrolysis of the phosphoenzyme appears to be the limiting
step in nucleotidase activity, they actually tend to accelerate
the latter reaction [31]. In the presence of eﬀectors both activ-
ities are increased, but phosphotransferase activity is fa-
voured towards nucleotidase activity and at physiological
pH and Pi concentrations phosphotransferase activity appears
predominant [10].4. Physiological activity
The respective importance of hydrolase and phosphotrans-
ferase activities of cN-II in cellular metabolism is unclear. In
the absence of phosphate acceptors substrates, or in the
absence of eﬀectors when phosphate acceptors are present,
cN-II essentially has a hydrolase function. As such its activ-
ity is optimal on (d)IMP (and (d)GMP, at least in vitro) at
pH 6.5.
cN-II is regulated by Pi and adenylate energy charge of the
cells [32]. In cases of low energy, anoxia or ischaemia, then
Fig. 2. Metabolic pathways for purine nucleotides in cells: anabolic pathway (–––), catabolic pathway (- - -) and salvage pathway (  ). IMP is the
starting point for adenine/guanine nucleotide synthesis. IMP can be produced de novo or via the salvage pathway. Abbreviations for enzyme names:
ADA, adenosine deaminase; AdK, adenosine kinase; AK, adenylate kinase; APRT, adenine phosphoribosyltransferase; dGK, deoxyguanosine
kinase; GUK, guanylate kinase; HGPRT, hypoxanthine–guanine phosphoribosyltransferase; IMPDH, inosine monophosphate dehydrogenase;
NDPK, nucleoside diphosphate kinase; PNP, purine nucleoside phosphorylase; RR, ribonucleotide reductase.
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from degrading IMP and probably GMP. This limits purine
nucleotide losses as diﬀusible nucleosides [33,34]. Importantly,
cN-II has a high activity in avian liver, an organ central to pre-
formed purine supply for other organs through erythrocyte
transport [1,35] and to purine nucleotide degradation into uric
acid. This outlines the signiﬁcance of cN-II as a catabolic en-
zyme, especially in the control of intracellular AMP and
IMP concentrations. cN-II thus relays AMP-deaminase, an
ATP-activated enzyme (AMPﬁ IMP, Fig. 2) in the so-called
‘‘IMP pathway’’ normally triggered under normoxic condi-
tions [36] or under metabolic stresses as after a high fructose
load [37]. In heart cells, the presence of a cytosolic AMP-
speciﬁc 5NT (cN-I, [38]) accounts for a diﬀerent AMP-degrad-
ing pathway leading to adenosine, especially important during
ischaemia since this compound is a known vasodilator regulat-
ing coronary blood ﬂow. cN-II may also have a direct role in
AMP hydrolysis where cN-I is absent as in polymorphonuclear
leucocytes [39], although with a predictably low activity at
physiological Pi concentration.
On the other hand, it was shown that cN-II mainly be-
haves as a phosphotransferase under physiological Pi and
ATP concentrations. As a phosphotransferase enzyme, cN-
II has optimal pH about physiological values (7.4) diﬀerent
from nucleotidase [31]. It is involved in the phosphorylation
of nucleosides that are not identiﬁed substrates of any kinase
yet, such as inosine and xanthosine [40], oﬀering an alterna-
tive salvage pathway for those nucleosides. cN-II may also
enable dIMP formation from IMP as a donor and deoxyino-
sine as an acceptor of phosphate. This reaction, followed by
interconversion to dAMP or dGMP, can bypass the ribonu-
cleotide reductase pathway [10]. Eventually, cN-II phosphor-
ylates several antiviral nucleoside analogues such as 2 0,
3 0-dideoxyinosine, acyclovir or 8-azaguanosine [10], although
these processes are unlikely to contribute signiﬁcantly tonucleoside analogue activation [41]. Rather, cN-II as a
nucleotidase may be involved in nucleoside analogue resis-
tance by reversing their functional anabolism as discussed
hereunder.5. Biological and clinical data on cN-II
In total cells, cN-II is implicated in a substrate cycle regulat-
ing the concentration of intracellular nucleotides. This has
been shown in cN-II overexpressing transfected cells with
lower ribonucleotide levels and increased secretion of inosine
and guanosine nucleotides [42–44].
Several studies suggest that cN-II is involved in resistance
to nucleoside analogues used in treatment for haematologi-
cal malignancies and some solid tumours. Firstly, inducing
resistance to nucleoside analogues in cell lines by prolonged
incubation with increasing concentrations of these drugs, re-
sulted in some cases in increased cN-II expression [45,46].
Secondly, patients having poor outcome of treatment with
nucleoside analogues showed higher cN-II expression level,
or enzyme activity, than patients with good response [47–
49]. We have shown that the monophosphorylated derivative
of ﬂudarabine, a nucleoside analogue used in the treatment
of haematological malignancies, is a substrate of cN-II in vi-
tro (Jordheim, L. P. et al., unpublished data). Our result has
been straightened by the observation that in blood cells
from chronic lymphocytic leukaemia patients, the ﬂudara-
bine-monophosphate degrading activity is correlated to cN-
II activity [50]. These observations suggest a direct role of
cN-II in the resistance to ﬂudarabine; however, a diﬀerent
study has shown that other monophosphates of nucleoside
analogues are not substrates for cN-II [51]. It seems never-
theless that in patients, in addition to possibly dephosphor-
ylate monophosphate derivatives of nucleoside analogues,
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response to nucleoside analogues by regulating the intracel-
lular concentrations of physiological nucleotides.6. Conclusions and perspectives
This review outlines the main known aspects of cN-II activ-
ity, an enzyme with several possible functions and complex
regulatory features that have not been fully understood yet.
Because of its pivotal role in intracellular metabolism, its reg-
ulated bifunctional nature, its elevated activity in some tumour
cells and its involvement in several alternative metabolic path-
ways, cN-II deserves particular interest. Full understanding of
its activity, possibly from structural data, would certainly be
beneﬁcial to the comprehension and control of cellular metab-
olism especially for clinical purpose. The development of spe-
ciﬁc cN-II inhibitors [52] or new compounds with lower aﬃnity
for cN-II may prevent drug resistance and improve existing
treatments.
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